Immuneering (IMRX) AI Stock Analysis

• Market Cap: $46.29M
• Dividend Yield: N/A
• Average Volume (3M): 174.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.75
• Revenue Growth: N/A
• EPS Growth: -7.78%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -2.03
• Shares Outstanding: 35,887,253
• 10 Day Avg. Volume: 125,468
• 30 Day Avg. Volume: 174,678
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2910.98
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 830.23% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

Immuneering's stock score is primarily impacted by its poor financial performance, with ongoing losses and negative cash flows posing significant risks. Technical analysis suggests neutral momentum, while valuation is unattractive due to the negative P/E ratio. Overall, the stock is risky with limited short-term upside potential.

Positive Factors

Clinical Data

IMM-1-104 plus chemotherapy combinations in PDAC have demonstrated approximately 50% objective response rate higher than the current standard of care.

Leadership

The appointment of Dr. Igor Matushansky as the CMO brings extensive oncology drug development expertise to the company.

Partnerships

Partnering with a global pharmaceutical company like Regeneron provides external validation of Immuneering's technology.

Negative Factors

Earnings

IMRX reported an EPS of -$0.58 for 4Q24, lower than consensus of -$0.43 with slightly higher R&D ($0.9M var).

Stock Performance

Despite the positive data, the stock has surprisingly declined since the announcement.

Immuneering Business Overview & Revenue Model

Company Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

How the Company Makes Money

Immuneering makes money primarily through the development and commercialization of its proprietary drug candidates. The company invests in research and development to advance its pipeline of therapies, with the potential for revenue generation upon successful clinical trials and regulatory approvals. Key revenue streams include milestone payments and royalties from partnerships with larger pharmaceutical companies that may license Immuneering's technology or drug candidates. Additionally, the company may engage in collaborations or licensing agreements to leverage its computational biology platform, providing further financial opportunities.

Immuneering Financial Statement Overview

Summary

Immuneering is facing significant financial challenges, characterized by consistent losses and negative cash flows. The company's ability to generate revenue is concerning, and its operational inefficiencies are reflected in its income statement. While the balance sheet shows a strong equity position, historical leverage issues remain a risk. Cash flow constraints indicate a reliance on external financing to support operations.

Income Statement

Immuneering has consistently reported zero or negative revenue over recent years, indicating significant challenges in generating sales. The gross profit margin is consistently negative or zero, and the net profit margin is deeply negative due to ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a relatively strong equity base with a decreasing trend in total debt. However, the company's equity ratio is fluctuating, and the company has experienced negative stockholders' equity in certain periods, indicating potential financial distress. The debt-to-equity ratio is concerning in some years, pointing to historical leverage issues.

Cash Flow

Operating and free cash flows have been negative, indicating challenges in generating cash from operations. This is coupled with a high dependence on financing activities. The free cash flow to net income ratio cannot be calculated due to persistent net losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	316.95K	2.08M	2.31M
	Gross Profit
0.00	-764.14K	158.83K	926.89K	1.03M
	EBIT
-64.07B	-58.41M	-51.74M	-33.89M	-17.08M
	EBITDA
-64.07B	-58.06M	-51.47M	-33.68M	-17.00M
	Net Income Common Stockholders
-61.04B	-53.47M	-49.28M	-33.54M	-17.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
36.14B	85.67M	105.52M	149.20M	37.09M
	Total Assets
52.71B	102.58M	122.37M	166.70M	38.42M
	Total Debt
4.16B	4.46M	4.84M	5.36M	621.09K
	Net Debt
-31.98B	-54.94M	-67.80M	-69.52M	-36.47M
	Total Liabilities
11.33B	12.01M	12.52M	10.72M	60.90M
	Stockholders Equity
41.39B	90.58M	109.85M	155.98M	-22.48M
Cash Flow		Free Cash Flow
-55.08M	-49.31M	-44.84M	-30.91M	-14.67M
	Operating Cash Flow
-55.00M	-48.97M	-44.10M	-30.85M	-14.62M
	Investing Cash Flow
26.43M	7.30M	41.83M	-75.62M	-53.41K
	Financing Cash Flow
5.30M	28.44M	19.00K	144.26M	37.98M

Immuneering Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRX, the sentiment is Negative. The current price of 1.29 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.67, and below the 200-day MA of 1.76, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.67 is Neutral, neither overbought nor oversold. The STOCH value of 11.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMRX.

Immuneering Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	79 Outperform	$9.89B	19.94	23.13%	―	18.49%	176.71%
INCY	66 Neutral	$11.67B	210.07	0.76%	―	14.76%	-88.32%
VRTX	64 Neutral	$123.99B	―	-3.15%	―	11.64%	-114.72%
BPMC	52 Neutral	$5.24B	―	-31.26%	―	104.04%	87.80%
ALNY	50 Neutral	$30.30B	―	-414.62%	―	22.97%	38.54%
Sector *	48 Neutral	$6.36B	1.24	-44.94%	2.70%	18.33%	1.47%
IMRX	37 Underperform	$46.29M	―	-92.51%	―	―	-7.78%